Pathstone Holdings
CRL icon

Pathstone Holdings’s Charles River Laboratories CRL Stock Holding History

Pathstone Holdings’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Sell
7,422
-685
-8% -$122K ﹤0.01% 1210
2026
Q1 		$1.4M Buy
8,107
+1,458
+22% +$270K 0.01% 1237
2025
Q4 		$1.33M Buy
6,649
+505
+8% +$91.6K 0.01% 1259
2025
Q3 		$961K Sell
6,144
-30
-0.5% -$4.76K ﹤0.01% 1448
2025
Q2 		$937K Buy
6,174
+1,977
+47% +$264K ﹤0.01% 1429
2025
Q1 		$633K Buy
4,197
+441
+12% +$73.9K ﹤0.01% 1604
2024
Q4 		$693K Sell
3,756
-809
-18% -$156K ﹤0.01% 1569
2024
Q3 		$899K Buy
4,565
+48
+1% +$9.97K ﹤0.01% 1428
2024
Q2 		$933K Buy
4,517
+548
+14% +$124K ﹤0.01% 1372
2024
Q1 		$1.08M Sell
3,969
-889
-18% -$212K 0.01% 1240
2023
Q4 		$1.15M Buy
+4,858
New +$955K 0.01% 1003

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Pathstone Holdings's CRL Position: Q2 2026 in Review

Pathstone Holdings reduced its Charles River Laboratories (CRL) stake by 8.4% in Q2 2026, selling an estimated $122K and leaving 7,422 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1210.

Pathstone Holdings first reported a position in CRL in Q4 2023 and has held it in 11 quarters since. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Pathstone Holdings held 7,422 shares of Charles River Laboratories worth $1.68M as of Q2 2026.
  • Pathstone Holdings sold 685 Charles River Laboratories shares in Q2 2026, an estimated $122K.
  • Charles River Laboratories made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1210 holding.
  • Pathstone Holdings first reported a position in Charles River Laboratories in Q4 2023 and has held it in 11 quarters since.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.